Quadrivalent influenza vaccine (recombinant, prepared in cell culture)

This medicine is authorised for use in the European Union.


Supemtek is a vaccine used to protect adults against influenza (flu).

Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time.

Supemtek contains proteins of four different influenza A and B virus strains (type A-H1N1, type A-H3N2 and two type B strains), chosen based on the official recommendation for the annual flu season.

This EPAR was last updated on 26/07/2023

Authorisation details

Product details
Agency product number
Active substance
  • Influenza A virus subtype H1N1 haemagglutinin, recombinant
  • Influenza A virus subtype H3N2 haemagglutinin, recombinant
  • Influenza B virus Victoria lineage haemagglutinin, recombinant
  • Influenza B virus Yamagata lineage haemagglutinin, recombinant
International non-proprietary name (INN) or common name
Quadrivalent influenza vaccine (recombinant, prepared in cell culture)
Therapeutic area (MeSH)
Influenza, Human
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Pasteur
Date of issue of marketing authorisation valid throughout the European Union
Contact address

14 Espace Henry Vallée
69007 Lyon

Product information

20/07/2023 Supemtek - EMEA/H/C/005159 - II/0011/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Supemtek is indicated for active immunization for the prevention of influenza disease in adults.

Supemtek should be used in accordance with official recommendations.

Assessment history

Related content

How useful was this page?

Add your rating